Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Kimiko Koiwa"'
Autor:
Masahiro Sawa, Tomomi Hata, Kazuhiro Takahashi, Hiroshi Matsubara, Toshihiro Nakamura, Hisayoshi Matsushima, Mai Miyata, Nobushige Numa, Youichi Watanabe, Hiromitsu Kozuka, Yukinori Endo, Sadao Takeuchi, Masanobu Izaki, Tetsuo Tsuchiya, Hidetoshi Saito, Tatsuhiko Yajima, Yasuhiro Tani, Tetsuji Hirato, Tadahiro Kiguchi, Hiromasa Nomura, Toshio Inbe, Hiroyuki Niino, Remi Ota, Akira Morita, Yukihiro Sakamoto, Minoru Osada, Yukinori Oda, Mitsunobu Iwasaki, Hiroaki Nishikawa, Hirofumi Takikawa, Hidetaka Asoh, Makoto Hino, Toshiaki Kondo, Fumio Aiki, Ichiro Takano, Katsuhiko Tashiro, Kimiko Koiwa, Takayuki Nagataki, Atsuo Kawana, Hiroshi Takebayashi, Kaoru Hoshino, Hiroshi Hayashi, Hiroki Habazaki, Makoto Sekine, Kouji Yasuda, Hiroyasu Kojima, Ei Uchida, Tetsuya Tsuda, Yoshitaka Misaka, Tatsuya Kikuchi, Tsutomu Morikawa, Joonhaeng Kang, Takumi Kozaki, Tomoyuki Fujinami, Shinji Yae, Manabu Inoue, Ayumu Matsumoto, Kenichi Shimizu, Junji Sasano, Yoshinao Hoshi, Katsutoshi Matsumoto, Masato Suzuki, Hiroaki Tsuchiya
Publikováno v:
Journal of The Surface Finishing Society of Japan. 71:96-182
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd4560a8e2c2ff3d236b3c9856007847
https://doi.org/10.4139/sfj.71.96
https://doi.org/10.4139/sfj.71.96
Autor:
Hoai‐Thu Thai, Kimiko Koiwai, Yoshihisa Shitara, Hirotaka Kazama, Jean‐Baptiste Fau, Dorothée Semiond, Christine Veyrat‐Follet
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 12, Pp 1846-1858 (2023)
Abstract This study aimed to support dosing regimen selection for isatuximab as a single agent or in combination with dexamethasone for Japanese patients with relapsed/refractory multiple myeloma (RRMM). A joint model characterizing the dynamics of s
Externí odkaz:
https://doaj.org/article/daa28da7c7994013bf748c2247ab7421
Autor:
Kimiko Koiwa, Wataru Yamamoto
Publikováno v:
Journal of The Surface Finishing Society of Japan. 68:282-285
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46dc27f73dff4db75c3be70aef2ca865
https://doi.org/10.4139/sfj.68.282
https://doi.org/10.4139/sfj.68.282
Autor:
Kimiko KOIWA
Publikováno v:
Journal of the Surface Finishing Society of Japan. 67:206-209
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eacddbc763b704b736c86f947c126be8
https://doi.org/10.4139/sfj.67.206
https://doi.org/10.4139/sfj.67.206
Autor:
Fatiha Rachedi, Kimiko Koiwai, Nadia Gaudel‐Dedieu, Bernard Sebastien, Hoai‐Thu Thai, Claire Brillac, Jean Baptiste Fau, Laurent Nguyen, Helgi van de Velde, Christine Veyrat‐Follet, Dorothée Semiond
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 6, Pp 766-777 (2022)
Abstract Isatuximab is an approved anti‐CD38 monoclonal antibody with multiple antitumor modes of action. An exposure‐response (E‐R) analysis using data from patients with relapsed/refractory multiple myeloma (RRMM) enrolled in a phase Ib clini
Externí odkaz:
https://doaj.org/article/72a8ca4364ed43ceb08268319c1c852e
Autor:
Kimiko Koiwai, Raouf El‐Cheikh, Hoai‐Thu Thai, Claire Brillac, Jean‐Baptiste Fau, Christine Veyrat‐Follet, Marie‐Laure Risse, Helgi van deVelde, Dorothée Semiond, Laurent Nguyen
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 928-940 (2021)
Abstract This analysis describes the pharmacokinetic/pharmacodynamic (PK/PD) modeling framework that supported selection of the isatuximab (anti‐CD38 monoclonal antibody) dosing regimen alongside its early clinical development in patients with rela
Externí odkaz:
https://doaj.org/article/af2cc48054174339a0403cbbf840ec73
Autor:
Jean‐Baptiste Fau, Raouf El‐Cheikh, Claire Brillac, Kimiko Koiwai, Nathalie Mace, Frank Campana, Dorothee Semiond, Laurent Nguyen
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 11, Pp 649-658 (2020)
Isatuximab, a monoclonal antibody (mAb) of immunoglobulin G (IgG) isotype, specifically targets the cluster of differentiation 38 antigen overexpressed in malignant plasma cells. Isatuximab is used to treat multiple myeloma (MM), characterized by the
Externí odkaz:
https://doaj.org/article/0b977e74df2045d28990c4247039121a